Targeted cancer therapy: From bench to bedside to patient

Journal of Clinical Oncology

Volumn 32, Issue 4, 2014, Pages 268-270

  Gellad, Walid F ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

CANCER PATIENT; CHRONIC MYELOID LEUKEMIA; DRUG COST; EDITORIAL; HUMAN; MEDICATION COMPLIANCE; MOLECULARLY TARGETED THERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK ASSESSMENT; COST; DRUG ANTAGONISM; ECONOMICS; FEMALE; MALE; NOTE; STATISTICS;

ANTINEOPLASTIC AGENTS; BENZAMIDES; COST SHARING; DRUG COSTS; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MEDICATION ADHERENCE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 84897019272     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.53.8413     Document Type: Editorial

References (28)

1. Mauro MJ, O'Dwyer M, Heinrich MC, et al: STI571: A paradigm of new agents for cancer therapeutics. J Clin Oncol 20:325-334, 2002 (Pubitemid 34032628)
2. Druker BJ, Guilhot F, O'Brien SG, et al: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New Engl J Med 355:2408-2417, 2006 (Pubitemid 44903745)
3. DiMatteo MR, Giordani PJ, Lepper HS, et al: Patient adherence and medical treatment outcomes: A meta-analysis. Med Care 40:794-811, 2002
4. Sabate E: Adherence to Long-Term Therapies: Evidence for Action. Geneva, Switzerland, World Health Organization, 2003
5. Fischer MA, Stedman MR, Lii J, et al: Primary medication non-adherence: Analysis of 195,930 electronic prescriptions. J Gen Intern Med 25:284-290, 2010
6. IMS Institute for Healthcare Informatics: Avoidable costs in U.S. healthcare: The $200 billion opportunity from using medicines more responsibly. http://www.imshealth.com/deployedfiles/imshealth/Global/Content/ Corporate/IMS%20Institute/RUOM-2013/IHII-Responsible-Use-Medicines-2013.pdf
7. Gebbia V, Bellavia G, Ferrau F, et al: Adherence, compliance and persistence to oral antineoplastic therapy: A review focused on chemotherapeutic and biologic agents. Expert Opin Drug Saf 1:S49-S59, 2012 (suppl)
8. Partridge AH, Avorn J, Wang PS, et al: Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 94:652-661, 2002 (Pubitemid 34552485)
9. Noens L, van Lierde MA, De Bock R, et al: Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study. Blood 113:5401-5411, 2009
10. Marin D, Bazeos A, Mahon FX, et al: Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28:2381-2388, 2010
11. Sandoval C, Giamelli J, Jayabose S: Imatinib mesylate noncompliance simulating chronic myeloid leukemia resistance. J Pediatr Hematol Oncol 25:507-508, 2003 (Pubitemid 36682761)
12. Ibrahim AR, Eliasson L, Apperley JF, et al: Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 117:3733-3736, 2011
13. Gellad WF, Grenard JL, Marcum ZA: A systematic review of barriers to medication adherence in the elderly: Looking beyond cost and regimen complexity. Am J Geriatr Pharmacother 9:11-23, 2011
14. Gellad WG, Grenard JL, McGlynn EA: A Review of Barriers to Medication Adherence: A Framework for Driving Policy Options. RAND Technical Report TR-765-MVC. 2009
15. Gibson TB, Ozminkowski RJ, Goetzel RZ: The effects of prescription drug cost sharing: A review of the evidence. Am J Manag Care. 11:730-740, 2005 (Pubitemid 41608213)
16. Goldman DP, Joyce GF, Zheng Y: Prescription drug cost sharing: Associations with medication and medical utilization and spending and health. JAMA 298:61-69, 2007 (Pubitemid 47026771)
17. Choudhry NK, Avorn J, Glynn RJ, et al: Full coverage for preventive medications after myocardial infarction. New Engl J Med 365:2088-2097, 2011
18. Dusetzina SB, Winn AN, Abel GA, et al: Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol 32:306-311, 2014
19. Neugut AI, Subar M, Wilde ET, et al: Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol 29:2534-2542, 2011
20. Wu EQ, Johnson S, Beaulieu N, et al: Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin 26:61-69, 2010
21. Partridge AH, Wang PS, Winer EP, Avorn J: Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21:602-606, 2003 (Pubitemid 46621892)
22. Thorpe CT, Bryson CL, Maciejewski ML, et al: Medication acquisition and self-reported adherence in veterans with hypertension. Med Care 47:474-481, 2009
23. Spoelstra SL, Given BA, Given CW, et al: Issues related to overadherence to oral chemotherapy or targeted agents. Clin J Oncol Nurs A1-A6, 2013
24. Kimmel SE, Troxel AB: Novel incentive-based approaches to adherence. Clin Trials 9:689-695, 2012
25. Granger BB, Bosworth HB: Medication adherence: Emerging use of technology. Curr Opin Cardiol 26:279-287, 2011
26. Byrd JC, Furman RR, Coutre SE, et al: Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. New Engl J Med 369:32-42, 2013
27. Wang ML, Rule S, Martin P, et al: Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. New Engl J Med 369:507-516, 2013
28. Shaw AT, Kim DW, Nakagawa K, et al: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. New Engl J Med 368:2385-2394, 2013